David R. Hout
About
David R. Hout is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Virology.
According to data from OpenAlex, David R. Hout has authored 32 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 10 papers in Virology. Recurrent topics in David R. Hout's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and HIV Research and Treatment (10 papers). David R. Hout is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and HIV Research and Treatment (10 papers). David R. Hout collaborates with scholars based in United States, Canada and China. David R. Hout's co-authors include Edward B. Stephens, Erik Pacyniak, Robert S. Seitz, Brock L. Schweitzer, Stephan W. Morris, Lavanya Krishnan, Jin-Woo Ahn, Alan Engelman, Jiong Shi and Vaibhav B. Shah and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
David R. Hout
30 papers receiving 613 citations
Peers
David R. Hout
Atuhani S. Burnett United States
Kate Poropatich United States
Adrien Saliou France
Graziella Becker‐Pergola United States
Evelien Naessens Belgium
Deepa Jeyakumar United States
Silvia Cerboni France
Johanna A. Smith United States
Julia Dietz Germany
Jean‐Marc Navarro France
Citations per year, relative to David R. Hout David R. Hout (= 1×)
peers
Atuhani S. Burnett
Countries citing papers authored by David R. Hout
Since
Specialization
Citations
This map shows the geographic impact of David R. Hout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Hout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Hout more than expected).
Fields of papers citing papers by David R. Hout
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David R. Hout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Hout. The network helps show where David R. Hout may publish in the future.
Co-authorship network of co-authors of David R. Hout
This figure shows the co-authorship network connecting the top 25 collaborators of David R. Hout. A scholar is included among the top collaborators of David R. Hout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Hout. David R. Hout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Saltman, David L., Matthew G. Varga, Nicole S. Croteau, et al.. (2022). 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clinical Lung Cancer. 24(2). 137–144.
2.
Jain, Amit, Emily J. Miller, Robert S. Seitz, et al.. (2022). Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC Cancer. 22(1). 407–407.
3.
Varga, Matthew G., et al.. (2022). The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer.. Journal of Clinical Oncology. 40(16_suppl). 4058–4058.
4.
Iwase, Toshiaki, Lajos Pusztai, Kim Blenman, et al.. (2020). Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 3117–3117.
5.
Fernández, José Rodrigo Espinosa, Bedrich L. Eckhardt, Jangsoon Lee, et al.. (2020). Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS ONE. 15(4). e0231953–e0231953.
6.
Funakoshi, Yohei, Ying Wang, Takashi Semba, et al.. (2019). Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS ONE. 14(9). e0222336–e0222336.
7.
Harano, Kenichi, Ying Wang, Bora Lim, et al.. (2018). Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE. 13(10). e0204513–e0204513.
8.
Jovanović, Bojana, Quanhu Sheng, Robert S. Seitz, et al.. (2017). Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer. 17(1). 241–241.
9.
Ring, Brian Z., David R. Hout, Stephan W. Morris, et al.. (2016). Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 16(1). 143–143.
10.
Berry, Brian, et al.. (2015). Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease. BMC Research Notes. 8(1). 308–308.
11.
Schweitzer, Brock L., et al.. (2013). Abstract 1930: The unknown piece of the pie: Molecular markers in triple-negative lung cancer.. Cancer Research. 73(8_Supplement). 1930–1930.
12.
Hout, David R., et al.. (2006). A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian–human immunodeficiency virus (SHIVKU-1bMC33) susceptible to rimantadine. Virology. 348(2). 449–461.
13.
Pacyniak, Erik, et al.. (2005). Identification of a Region within the Cytoplasmic Domain of the Subtype B Vpu Protein of Human Immunodeficiency Virus Type 1 (HIV-1) That Is Responsible for Retention in the Golgi Complex and Its Absence in the Vpu Protein from a Subtype C HIV-1. AIDS Research and Human Retroviruses. 21(5). 379–394.
14.
Hout, David R., Erik Pacyniak, David M. Pinson, et al.. (2005). Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIVTM) that is less pathogenic for pig-tailed macaques. Virology. 339(1). 56–69.
15.
Hout, David R., Erik Pacyniak, Barbara Fegley, et al.. (2005). Substitution of the transmembrane domain of Vpu in simian–human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques. Virology. 344(2). 541–559.
16.
Pacyniak, Erik, David R. Hout, Eric Nerrienet, et al.. (2005). Vpu-mediated CD4 down-regulation and degradation is conserved among highly divergent SIVcpz strains. Virology. 335(1). 46–60.
17.
Hout, David R., Erik Pacyniak, Barbara Fegley, et al.. (2004). Fusion of the upstream vpu sequences to the env of simian human immunodeficiency virus (SHIVKU-1bMC33) results in the synthesis of two envelope precursor proteins, increased numbers of virus particles associated with the cell surface and is pathogenic for pig-tailed macaques. Virology. 323(1). 91–107.
18.
Hout, David R., et al.. (2004). Vpu: A Multifunctional Protein that Enhances the Pathogenesis of Human Immunodeficiency Virus Type 1. Current HIV Research. 2(3). 255–270.
19.
Singh, Dinesh Kumar, Darcy M. Griffin, Erik Pacyniak, et al.. (2003). The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4+ T cell loss caused by the simian–human immunodeficiency virus SHIVKU-lbMC33 in pig-tailed macaques. Virology. 313(2). 435–451.
20.
Hout, David R., Dinesh Kumar Singh, Nancy E.J. Berman, et al.. (2000). A Molecular Clone of Simian-Human Immunodeficiency Virus (ΔvpuSHIVKU-1bMC33) with a Truncated, Non-Membrane-Bound Vpu Results in Rapid CD4+ T Cell Loss and Neuro-AIDS in Pig-Tailed Macaques. Virology. 272(1). 112–126.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Atuhani S. Burnett Breakdown of academic impact, for papers by Kate Poropatich Breakdown of academic impact, for papers by Adrien Saliou Breakdown of academic impact, for papers by Graziella Becker‐Pergola Breakdown of academic impact, for papers by Evelien Naessens Breakdown of academic impact, for papers by Deepa Jeyakumar Breakdown of academic impact, for papers by Silvia Cerboni Breakdown of academic impact, for papers by Johanna A. Smith Breakdown of academic impact, for papers by Julia Dietz Breakdown of academic impact, for papers by Jean‐Marc Navarro